Opinion/decision on a Paediatric investigation plan (PIP): Bimervax, SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion homodimer - XBB.1.16-XBB.1.16 variant,SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion

Opinion/decision on a Paediatric investigation plan (PIP): Bimervax, SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion homodimer - XBB.1.16-XBB.1.16 variant,SARS-CoV-2 virus recombinant spike protein receptor binding domain fusion heterodimer (B.1.351 and B.1.1.7 strains) (beta-alpha variants), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0253/2024